South Korean biotech company developing engineered, allogeneic, off-the-shelf CAR-NK cell therapies for cancer
South Korean biotech company developing engineered, allogeneic, off-the-shelf CAR-NK cell therapies for cancer. Its programs combine dual-target cancer recognition with tumor-microenvironment modulation, including UCI-101, a CD19/CD22 dual-specific CAR-NK for blood cancers, and UCI-112, which targets mesothelin and secretes TGF-beta signaling-inhibitory peptides.